1895296-01-1 Usage
General Description
3,3,3-trifluoro-2,2-dimethylpropan-1-ol is a specialized chemical compound with unique properties as a result of its molecular structure. It contains multiple elements, notably carbon, hydrogen, fluorine, and oxygen. These are arranged in a specific formation, leading to its unique characteristics. 3,3,3-trifluoro-2,2-diMethylpropan-1-ol is categorized as an aliphatic organofluorine compound, which simply means it contains carbon-fluorine bonds arranged in a chain structure. The presence of the trifluoro group, which consists of three fluorine atoms, contributes to its high stability. In addition, the two methyl groups, each containing one carbon and three hydrogen atoms, add to its complexity. Lastly, the presence of a hydroxyl group (-OH) classifies it as an alcohol. The exact properties of this compound, such as its reactivity and physical state, depend on the specifics of its application and ambient conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1895296-01-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,9,5,2,9 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1895296-01:
(9*1)+(8*8)+(7*9)+(6*5)+(5*2)+(4*9)+(3*6)+(2*0)+(1*1)=231
231 % 10 = 1
So 1895296-01-1 is a valid CAS Registry Number.
1895296-01-1Relevant articles and documents
6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
-
Page/Page column 52, (2021/05/21)
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
Paragraph 0559-0560; 0568-0569; 0590; 0593-0594, (2021/08/13)
The disclosure provides processes for preparing a compound of Formula (I).
PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
-
Paragraph 0526; 0527; 0550; 0551, (2019/08/20)
A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
